Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p
…, D Sun, AC Salzberg, N Jones, RT Bushey… - … of Pharmacology and …, 2014 - ASPET
The UDP-glucuronosyltransferase (UGT) 1A enzymes are involved in the phase II metabolism
of many important endogenous and exogenous compounds. The nine UGT1A isoforms …
of many important endogenous and exogenous compounds. The nine UGT1A isoforms …
[PDF][PDF] A therapeutic antibody for cancer, derived from single human B cells
RT Bushey, MA Moody, NL Nicely, BF Haynes… - Cell reports, 2016 - cell.com
Some patients with cancer never develop metastasis, and their host response might provide
cues for innovative treatment strategies. We previously reported an association between …
cues for innovative treatment strategies. We previously reported an association between …
Importance of UDP-glucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism
RT Bushey, DF Dluzen, P Lazarus - Drug metabolism and disposition, 2013 - ASPET
… Recently completed studies have also shown that UGT2A1 is unable to metabolize substrates
using these alternate sugars (RT Bushey and P. Lazarus, unpublished data), suggesting …
using these alternate sugars (RT Bushey and P. Lazarus, unpublished data), suggesting …
Complement factor H antibodies from lung cancer patients induce complement-dependent lysis of tumor cells, suggesting a novel immunotherapeutic strategy
MJ Campa, EB Gottlin, RT Bushey, EF Patz Jr - Cancer immunology research, 2015 - AACR
Abstract Characterization of the humoral immune response in selected patients with cancer
who uniformly do well may lead to the development of novel therapeutic strategies. We have …
who uniformly do well may lead to the development of novel therapeutic strategies. We have …
Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis
RT Bushey, G Chen, AS Blevins-Primeau… - Pharmacogenetics …, 2011 - journals.lww.com
… RT-PCR assays were performed using pooled RNA from at least three normal samples for
each organ/tissue. Two micrograms of RNA was used for RT using a Superscript II RT … by RT-…
each organ/tissue. Two micrograms of RNA was used for RT using a Superscript II RT … by RT-…
Complement factor H: a novel innate immune checkpoint in cancer immunotherapy
…, EB Gottlin, MJ Campa, RT Bushey… - Frontiers in Cell and …, 2024 - frontiersin.org
The elimination of cancer cells critically depends on the immune system. However, cancers
have evolved a variety of defense mechanisms to evade immune monitoring, leading to …
have evolved a variety of defense mechanisms to evade immune monitoring, leading to …
Identification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility
RT Bushey, P Lazarus - Journal of Pharmacology and Experimental …, 2012 - ASPET
… in multiple respiratory, digestive, and aerodigestive tract tissues (Bushey et al., 2011). In the
present study, RT-PCR amplification of UGT2A1 from pooled lung RNA yielded two distinct …
present study, RT-PCR amplification of UGT2A1 from pooled lung RNA yielded two distinct …
[HTML][HTML] Upregulation of complement proteins in lung cancer cells mediates tumor progression
…, MCM Weiser-Evans, EB Gottlin, RT Bushey… - Frontiers in …, 2023 - frontiersin.org
Introduction In vivo, cancer cells respond to signals from the tumor microenvironment resulting
in changes in expression of proteins that promote tumor progression and suppress anti-…
in changes in expression of proteins that promote tumor progression and suppress anti-…
[HTML][HTML] Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis
RT Bushey, EB Gottlin, MJ Campa, EF Patz Jr - Plos one, 2021 - journals.plos.org
Exosomes are a class of extracellular vesicles (EVs) that are mediators of normal intercellular
communication, but exosomes are also used by tumor cells to promote oncogenesis and …
communication, but exosomes are also used by tumor cells to promote oncogenesis and …
Antitumor immune mechanisms of the anti-complement factor H antibody GT103
RT Bushey, R Saxena, MJ Campa, EB Gottlin… - Molecular Cancer …, 2023 - AACR
Abstract Development of novel therapeutic antibodies that not only kill tumor cells but
modulate the adaptive immune response has the potential to produce long term anticancer …
modulate the adaptive immune response has the potential to produce long term anticancer …